127 related articles for article (PubMed ID: 29712692)
1. Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.
Mohamed AA; Xavier CP; Sukumar G; Tan SH; Ravindranath L; Seraj N; Kumar V; Sreenath T; McLeod DG; Petrovics G; Rosner IL; Srivastava M; Strovel J; Malhotra SV; LaRonde NA; Dobi A; Dalgard CL; Srivastava S
Cancer Res; 2018 Jul; 78(13):3659-3671. PubMed ID: 29712692
[TBL] [Abstract][Full Text] [Related]
2. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
Semaan L; Mander N; Cher ML; Chinni SR
BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
[TBL] [Abstract][Full Text] [Related]
4. New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives.
Eldhose B; Pandrala M; Xavier C; Mohamed AA; Srivastava S; Sunkara AD; Dobi A; Malhotra SV
ACS Med Chem Lett; 2021 Nov; 12(11):1703-1709. PubMed ID: 34790292
[TBL] [Abstract][Full Text] [Related]
5.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
6. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
7. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.
Wang X; Qiao Y; Asangani IA; Ateeq B; Poliakov A; Cieślik M; Pitchiaya S; Chakravarthi BVSK; Cao X; Jing X; Wang CX; Apel IJ; Wang R; Tien JC; Juckette KM; Yan W; Jiang H; Wang S; Varambally S; Chinnaiyan AM
Cancer Cell; 2017 Apr; 31(4):532-548.e7. PubMed ID: 28344039
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
[TBL] [Abstract][Full Text] [Related]
9. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
10. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
[TBL] [Abstract][Full Text] [Related]
11. Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.
Li L; Hobson L; Perry L; Clark B; Heavey S; Haider A; Sridhar A; Shaw G; Kelly J; Freeman A; Wilson I; Whitaker H; Nurmemmedov E; Oltean S; Porazinski S; Ladomery M
Br J Cancer; 2020 Sep; 123(6):1024-1032. PubMed ID: 32581342
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
13. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
Rahim S; Minas T; Hong SH; Justvig S; Çelik H; Kont YS; Han J; Kallarakal AT; Kong Y; Rudek MA; Brown ML; Kallakury B; Toretsky JA; Üren A
PLoS One; 2014; 9(12):e114260. PubMed ID: 25479232
[TBL] [Abstract][Full Text] [Related]
14. Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer.
Li C; Zhang J; Wu Q; Kumar A; Pan G; Kelvin DJ
Mol Cancer Ther; 2023 Mar; 22(3):306-316. PubMed ID: 36622760
[TBL] [Abstract][Full Text] [Related]
15. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
[TBL] [Abstract][Full Text] [Related]
17. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
Shao L; Kahraman N; Yan G; Wang J; Ozpolat B; Ittmann M
Prostate; 2020 Jan; 80(1):65-73. PubMed ID: 31614005
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
[TBL] [Abstract][Full Text] [Related]
19. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
20. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
